Stealth Biotherapeutics (MITO)

Stealth BioTherapeutics Corp is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide, which is currently in a phase 3 clinical trial to treat Barth syndrome. It is also in a phase 2/3 clinical trial for the treatment of Duchenne cardiomyopathy, a phase 2a clinical trial to treat Friedreich's ataxia, a phase 2 clinical trial for the treatment of dry age-related macular degeneration, a phase 2 clinical trial to treat Leber's hereditary optic neuropathy, and a phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20, which aims to treat complications of diabetes, renal diseases, ocular diseases, and neurodegenerative diseases such as Parkinson's, Alzheimer's, Huntington's, and ALS. Additionally, SBT-550 is being developed for rare neurological indications, and SBT-272 is a peptidomimetic that targets the mitochondria and stabilizes mitochondrial function under conditions of oxidative stress, along with SBT-550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.